Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Preliminary Phase Ib/II Data supports the controllable Safety and encouraging Efficacy in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL)

被引：0
|
作者：
Hutchings, M. [1 ]
Sureda, A. [2 ]
Terol, M. J. [3 ]
Bosch, F. [4 ]
Corradini, P. [5 ,6 ]
Stauffer, Larsen T. [7 ]
Rueda, Dominguez A. [8 ]
Panchal, A. [9 ]
Bottos, A. [10 ]
Carlile, D.
Wang, Y. [11 ]
de L'Etang, Filezac A. [10 ]
Tandon, M.
Sellam, G. [10 ]
Gritti, G. [12 ]
机构：
[1] Rigshosp, Copenhagen, Denmark
[2] Inst Catala Oncol Hosp, Barcelona, Spain
[3] Univ Valencia, Hosp Clin Univ INCLIVA, Valencia, Spain
[4] Univ Hosp Vall Hebron, Barcelona, Spain
[5] Univ Milan, Milan, Italy
[6] Fondazione IRCCS Ist Nazl Tumori, Milan, Italy
[7] Odense Univ Hosp, Odense, Denmark
[8] Reg & Virgen Victoria Univ Hosp, Malaga, Spain
[9] Roche Prod Ltd, Welwyn Garden City, Herts, England
[10] F Hoffmann Roche Ltd, Basel, Switzerland
[11] F Hoffmann Roche Ltd, Shanghai, Peoples R China
[12] Ospedale Papa Giovanni 23, Bergamo, Italy
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V195
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [41] Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    Van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Marie Jose
    Schuster, Stephen J.
    Salles, Gilles Andre
    Maziarz, Richard Thomas
    Anak, Oezlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    BLOOD, 2017, 130
  • [42] Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study
    Yasenchak, Christopher
    Kim, Jeong-A
    Hahn, Uwe
    Kim, Won-Seog
    Fleury, Isabelle
    Laribi, Kamel
    Bergua Burgues, Juan Miguel
    Bouabdallah, Krimo
    Forward, Nicholas
    Bijou, Fontanet
    MacDonald, David
    Portell, Craig
    Ghesquieres, Herve
    Nowakowski, Grzegorz
    Rustia, Evelyn
    Fanale, Michelle
    Jie, Fei
    Bartlett, Nancy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S490 - S491
  • [43] Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Chen, Robert W.
    Ansel, Stephen Maxted
    Zinzani, Pier Luigi
    Vacirca, Jeffrey L.
    Lopez-Guillermo, Armando
    Hutchings, Martin
    Jurczak, Wojciech
    Hess, Georg
    Le Gouill, Steven
    Offner, Fritz
    Santoro, Armando
    Salles, Gilles A.
    Stypinski, Darla
    Laird, Douglas
    Pavlov, Dmitri
    Andreola, Giovanna
    Fly, Kolette D.
    Woolfson, Adrian
    Collins, Graham P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Bell, Jill A.
    Cherepanov, Dasha
    Revicki, Dennis
    Speck, Rebecca M.
    Swett, Laura
    Stumpo, Kate
    Rong, Yuanxin
    Gordon, Leo I.
    QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
  • [45] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
    Tilly, Herve
    Morschhauser, Franck
    Bartlett, Nancy L.
    Sharman, Jeff
    Haioun, Corinne
    Kolibaba, Kathryn S.
    Chen, Andy
    Lamy, Thierry
    Jones, Surai
    Penuel, Elicia
    Lee, Calvin
    Salles, Gilles A.
    BLOOD, 2016, 128 (22)
  • [46] Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany
    Kambhampati, Swetha
    Shumilov, Evgenii
    Saumoy, Monica
    Herrera, Alex F.
    Tilly, Herve
    Lenz, Georg
    Thiruvengadam, Nikhil R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (04) : 771 - 775
  • [47] Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
    Vodicka, Prokop
    Benesova, Katerina
    Janikova, Andrea
    Prochazka, Vit
    Belada, David
    Mocikova, Heidi
    Steinerova, Katerina
    Duras, Juraj
    Karban, Josef
    Hanackova, Veronika
    Sykorova, Alice
    Obr, Ales
    Trneny, Marek
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 162 - 165
  • [48] Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S249 - S250
  • [49] Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
    Dal, Mehmet Sinan
    Ulu, Bahar Uncu
    Uzay, Ant
    Akay, Olga Meltem
    Besisik, Sevgi
    Yenerel, Mustafa Nuri
    Celik, Serhat
    Kaynar, Leylagul
    Yucel, Orhan Kemal
    Deveci, Burak
    Sonmez, Mehmet
    Mehtap, Ozgur
    Bekoz, Huseyin Saffet
    Sunu, Cenk
    Salim, Ozan
    Ulas, Turgay
    Karti, Sami
    Altuntas, Fevzi
    Ferhanoglu, Burhan
    Tuglular, Tulin Firat
    ANNALS OF HEMATOLOGY, 2023, 102 (01) : 133 - 140
  • [50] Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
    Mehmet Sinan Dal
    Bahar Uncu Ulu
    Ant Uzay
    Olga Meltem Akay
    Sevgi Beşışık
    Mustafa Nuri Yenerel
    Serhat Çelik
    Leylagül Kaynar
    Orhan Kemal Yücel
    Burak Deveci
    Mehmet Sönmez
    Özgür Mehtap
    Hüseyin Saffet Beköz
    Cenk Sunu
    Ozan Salim
    Turgay Ulaş
    Sami Kartı
    Fevzi Altuntaş
    Burhan Ferhanoğlu
    Tülin Fırat Tuğlular
    Annals of Hematology, 2023, 102 : 133 - 140
12345